The endocannabinoid system, explained for clinicians

What the ECS is

The endocannabinoid system (ECS) is a widespread lipid-signalling network that helps maintain physiological homeostasis across the nervous, immune, gastrointestinal and other systems. It comprises three functional parts: receptors, endogenous ligands (endocannabinoids) and the enzymes that synthesise and degrade those ligands. Phytocannabinoids such as THC and CBD act on, or modulate, this same system — which is why understanding the ECS is the foundation of cannabinoid medicine.

Receptors: CB1 and CB2

The two best-characterised receptors are G-protein-coupled:

• CB1 — densely expressed in the central and peripheral nervous system. CB1 activation modulates neurotransmitter release and mediates most of the psychoactive and analgesic effects of THC.
• CB2 — expressed mainly on immune cells and in peripheral tissues, with roles in inflammation and immune modulation.

Cannabinoids also interact with non-classical targets (for example TRPV1, PPARs and GPR55), which helps explain effects not fully accounted for by CB1/CB2 alone.

Endocannabinoids: anandamide and 2-AG

The principal endogenous ligands are anandamide (AEA) and 2-arachidonoylglycerol (2-AG). Unlike classical neurotransmitters they are synthesised on demand from membrane phospholipids and typically act as retrograde messengers — released post-synaptically to fine-tune pre-synaptic signalling.

Enzymes and endocannabinoid tone

Endocannabinoid signalling is terminated by hydrolysing enzymes — chiefly FAAH (for anandamide) and MAGL (for 2-AG). The balance of synthesis and degradation sets the prevailing endocannabinoid tone. The concept of altered tone in some chronic pain, mood and inflammatory states is an active area of research and part of the rationale for cannabinoid-based approaches.

Why it matters at the bedside

Because CB1 and CB2 have different distributions, the receptor and target profile of a given cannabinoid shapes both its therapeutic and adverse effects. This is the mechanistic backdrop for the practical differences between CBD and THC, for titration strategy in the dosage guide, and for the indication-specific evidence collected in the clinical evidence library.